BUFFALO, NY--(Marketwire - August 13, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) and founding partner Cleveland Clinic reported today that CBLI’s lead product, Protectan CBLB502, currently being developed as a radioprotectant and radiomitigator, demonstrated efficacy in animal models of tourniquet injury. This finding is the result of pre-clinical studies funded by a grant from the Department of Defense to research the use of Protectans in tourniquet and other ligation-reperfusion battlefield injuries, where blood flow is stopped and then restored after a prolonged period of time.
